Beacon Biosignals is positioned as the leading pharma-facing EEG analytics platform, using a foundation model trained on millions of hours of sleep EEG data to extract CNS drug biomarkers for clinical trial endpoints. Its $86M Series B, FDA-cleared Waveband device, and partnerships with Takeda and UCB place it among the most commercially advanced neurotech startups in the biopharma services segment.